---
figid: PMC7988944__13027_2021_359_Fig6_HTML
figlink: pmc/articles/PMC7988944/figure/Fig6/
number: F6
caption: HBV induces sorafenib resistance in liver cancer via upregulation of cIAP2
  expression. HBV infection induces cIAP2 expression through PI3K/Akt/NF-κB signaling
  pathway. The upregulated cIAP2 promotes cell survival by reducing caspase-3 level.
  The cIAP2-enhanced cell survival renders the cells more resistant to sorafenib treatment,
  while anti-HBV treatment with lamivudine can suppress the upregulation of cIAP2
  and consequently restore cancer cell sensitivity to sorafenib
pmcid: PMC7988944
papertitle: Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation
  of cIAP2 expression.
reftext: Shouhua Zhang, et al. Infect Agent Cancer. 2021;16:20.
pmc_ranked_result_index: '6139'
pathway_score: 0.965663
filename: 13027_2021_359_Fig6_HTML.jpg
figtitle: HBV induces sorafenib resistance in liver cancer via upregulation of cIAP2
  expression
year: '2021'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7988944__13027_2021_359_Fig6_HTML.html
  '@type': Dataset
  description: HBV induces sorafenib resistance in liver cancer via upregulation of
    cIAP2 expression. HBV infection induces cIAP2 expression through PI3K/Akt/NF-κB
    signaling pathway. The upregulated cIAP2 promotes cell survival by reducing caspase-3
    level. The cIAP2-enhanced cell survival renders the cells more resistant to sorafenib
    treatment, while anti-HBV treatment with lamivudine can suppress the upregulation
    of cIAP2 and consequently restore cancer cell sensitivity to sorafenib
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT2
  - AKT3
  - AKT1
  - NFKBIA
  - NFKB1
  - NFKB2
  - REL
  - RELA
  - RELB
  - Lamivudine
  - Sorafenib
genes:
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: IkBa
  symbol: IKBA
  source: hgnc_alias_symbol
  hgnc_symbol: NFKBIA
  entrez: '4792'
- word: NF-kB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: NF-kB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: NF-kB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: NF-kB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: NF-kB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
chemicals:
- word: Lamivudine
  source: MESH
  identifier: D019259
- word: Sorafenib
  source: MESH
  identifier: C471405
diseases: []
figid_alias: PMC7988944__F6
redirect_from: /figures/PMC7988944__F6
figtype: Figure
---
